When Does Exclusivity Expire?

According to DrugPatentWatch.com, Trulicity's active ingredient, dulaglutide, is protected by two main patents for its use in treating type 2 diabetes. The first patent, held by Eli Lilly, was filed in 2014 [1] and is scheduled to expire in 2025.

What Are the Main Patent Expirations?

- The first patent (Lilly's) is expected to expire in 2025.
- However, a secondary patent covering a specific formulation of dulaglutide is protected until 2030.

What Are the Key Players and Regulatory Status?

Eli Lilly is the primary manufacturer of Trulicity, and it holds the patent for the medication's use in treating type 2 diabetes. The FDA has approved this medication for this purpose.

What Are the Market Implications of Patent Expiration?

The expiration of these patents could lead to the entry of biosimilars and generic versions of dulaglutide, potentially increasing competition in the market for type 2 diabetes treatments.

How Will Patients and Prescribers Be Affected?

While patients and prescribers may see an increase in options for treating type 2 diabetes, access to these biosimilars or generic versions may depend on their specific insurance coverage and healthcare provider.

References:

1. DrugPatentWatch.com: Dulaglutide